

## Press release

## Melexis Q2 2016 results – Sales guidance increased

#### Intermediate declaration by the Board of Directors

Ieper, Belgium - July 27th, 2016, 07.00 hrs CET

<u>Sales for the second quarter of 2016</u> were 112.3 million EUR, an increase of 10% compared to the same quarter of the previous year and an increase of 3% compared to the previous quarter.

The EUR/USD exchange rate evolution had a negative impact of 2% compared to the same quarter of last year and a negative impact of 2% compared to the previous quarter.

Gross margin was 50.9 million EUR, an increase of 3% compared to the same quarter of last year.

R&D expenses were 14.4% of sales, G&A was at 4.6% of sales and Selling was at 1.9% of sales. The operating result was 27.7 million EUR, a decrease of 3% compared to the same quarter of last year and an increase of 1% compared to the previous quarter.

Net income was 23.1 million EUR or 0.57 EUR per share, a decrease of 7% compared to 24.9 million EUR or 0.62 EUR per share in the second quarter of 2015 and an increase of 1% compared to 22.8 million EUR or 0.57 EUR per share in the previous quarter.

<u>Sales for the first half year of 2016</u> were 221.7 million EUR, an increase of 13% compared to the first half year of 2015.

The EUR/USD exchange rate evolution had a positive impact of 1% compared to the same period last vear.

Gross margin was 100.2 million EUR, an increase of 3% compared to the same period last year.

The operating result was 55.2 million EUR, compared to 56.5 million EUR in the same half year of 2015, a decrease of 2%.

Net income was 46.0 million EUR or 1.14 EUR per share, a decrease of 12% compared to 52.0 million EUR or 1.29 EUR per share in the first half year of 2015.

#### Dividend

The Board of Directors decided to pay out an interim dividend of 1.30 EUR gross per share. The Melexis shares will start trading ex coupon on October 25, 2016 (opening of the market). The record date is October 26, 2016 (closing of the market) and the dividend will be payable as from October 27, 2016. After year end, the Board of Directors will decide if a final dividend is desirable.

### Outlook

Melexis expects sales in the third quarter of 2016 to be around the level of 116 million EUR. For full year 2016, Melexis expects sales growth to be around the level of 13-14%, instead of the 8 to 12% guidance so far. Melexis further expects a gross profit margin around 45% and an operating margin around 25%, all taking into account a EUR/USD exchange rate of 1.10.

#### **Business comment – Françoise Chombar, CEO:**

"Following a good start of the year, Melexis produces again a solid performance in the second quarter. Sales in the first half year increased 13% versus 1H2015, enabling us to increase our sales guidance for the full year. Our gross profit margin is expected to stay around 45% for the remainder of the year, as the strong demand for our products requires an increased focus on execution. Since Melexis grows



significantly stronger than the market, our strategy to accelerate our investments in R&D remains steadfast. In June, Melexis founded a new R&D center in Dresden, Germany, to support the execution of the Melexis innovation roadmap.

The main growth drivers in the second quarter were sensor interfaces and our magnetic sensor product lines.

In the second quarter, sales to automotive customers represented 89% of total sales. The portion of standard product (ASSPs) sales represented 60% of total sales."

The statutory auditors BDO Bedrijfsrevisoren Burg. Ven. CVBA, have confirmed that their review procedures, which have been substantially completed, have not revealed material adjustments which would have to be made to the accounting information included in this press release.

#### **Financial Calendar**

- Publication Q3 2016 Results: October 26, 2016
- Dividend pay date: October 27, 2016 (ex coupon on October 25, 2016)
- Publication FY 2016 Results: February 8, 2017

The company's results will be discussed in a **conference call** on Wednesday, July 27th, 2016 at 17 hrs CET. The conference call will be in English. You have to register for this conference call in advance. You can register by clicking on the following link and filling out the requested information:

https://eventreg2.conferencing.com/webportal3/reg.html? Acc=179908& Conf=222371

Conference ID: 959439.

After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes all participants must register individually if they wish to join the call.

A replay number for this call is available for 7 days after the end of the conference call. The replay number for this call is +32 2 290 17 05, access code: 959439.

For further information:

**Investor Relations** 

Phone: +32 13 67 07 79 Fax: +32 13 67 21 34

Email: investor@melexis.com

#### **About Melexis**

Melexis NV (Euronext Brussels: MELE) is a mixed signal semiconductor manufacturer. Melexis designs, develops, tests and markets advanced integrated semiconductor devices for the automotive industry. Our core experience supplying ICs for automotive electronics sustains the expansion into Application Specific Standard Products for industrial and consumer product applications. Melexis enthusiastically pursues its role as a component supplier whose innovations are the essential element in nearly every one of our customers' extraordinary systems. Melexis' products include sensor, communication, actuator ICs and Application Specific Integrated Circuits (ASICs). Further information about Melexis can be found at http://www.melexis.com.



#### Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forward-looking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new productions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.



### **Consolidated Income Statement**

CONFORM IFRS	Quarter ended 30/06/2016	Quarter ended 30/06/2015	Half Year ended 30/06/2016	Half Year ended 30/06/2015	Year ended 31/12/2015
in k EUR					audited
Sales	112,322	101,757	221,747	196,177	400,136
Cost of sales	-61,409	-52,145	-121,551	-99,367	-208,015
Gross Margin	50,913	49,612	100,196	96,810	192,121
R&D	-16,217	-14,100	-30,963	-26,812	-56,737
G&A	-5,160	-4,838	-9,877	-9,163	-19,090
Selling	-2,146	-2,182	-4,432	-4,363	-8,690
Other operating result	311		311		
Operating result	27,700	28,493	55,234	56,473	107,604
Financial result	-38	-423	-1,132	1,935	1,869
Income before taxes	27,661	28,069	54,101	58,408	109,473
Income taxes	-4,525	-3,184	-8,130	-6,379	-10,402
Net income	23,135	24,885	45,971	52,029	99,071
Net income per share in EUR	0.57	0.62	1.14	1.29	2.45

### **Consolidated Statement of Financial Position**

CONFORM IFRS in k EUR	Half Year ended 30/06/2016	Half Year ended 30/06/2015	Year ended 31/12/2015 audited
Current Assets :			
Cash and cash equivalents	95,321	80,931	73,838
Current investments		351	49
A/R Trade	54,169	50,626	51,243
A/R from related parties	7,111	7,115	1,999
Advance related parties			
Assets for current tax	664	925	1,384
Assets held for sale	0	1,210	289
Other current assets	8,492	7,659	5,237
Inventories	65,797	62,329	64,099
Total current assets	231,555	211,147	198,140
Non-current assets :			
Costs of incorporation			
Property, plant and equipment	96,454	79,221	90,300
Financial assets	6	6	6
Intangible fixed assets	6,944	6,219	7,440
A/R directors			
Other non-current assets	7	959	8
Deferred tax assets	8,484	11,612	10,877
Total non current assets	111,895	98,016	108,630
Total assets	343,450	309,163	306,770



1,189 4,046 21,680 20,397 8,306 6,713 1,854 1,331	1,497 5,155 15,504 8,871 5,380 6,190	7,046 15,247 10,791
4,046 21,680 20,397 8,306 6,713 1,854 1,331	5,155 15,504 8,871 5,380 6,190	1,627 7,046 15,247 10,791 6,543
4,046 21,680 20,397 8,306 6,713 1,854 1,331	5,155 15,504 8,871 5,380 6,190	7,046 15,247 10,791
4,046 21,680 20,397 8,306 6,713 1,854 1,331	5,155 15,504 8,871 5,380 6,190	7,046 15,247 10,791
4,046 21,680 20,397 8,306 6,713 1,854 1,331	5,155 15,504 8,871 5,380 6,190	7,046 15,247 10,791
21,680 20,397 8,306 6,713 1,854 1,331	15,504 8,871 5,380 6,190	15,247 10,791
20,397 8,306 6,713 1,854 1,331	8,871 5,380 6,190	10,791
8,306 6,713 1,854 1,331	5,380 6,190	
6,713 1,854 1,331	6,190	6 543
1,854 1,331		0,545
1,331	1 703	7,135
	1,702	3,258
	387	2,358
65,516	44,685	54,005
11,092	17,957	8,138
2,191	1,944	2,116
13,283	19,902	10,254
565	565	565
-3,818	-3,818	-3,818
-326	-389	-372
57	57	57
		153,308
45,971	52,029	99,071
		-6,311
	244,566	242,500
10	10	10
264,652	244,576	242,511
3/13 //50	309.163	306,770
	2,191 13,283  565  -3,818 -326  57 228,342 45,971 -6,149 264,641 10 264,652	2,191 1,944 13,283 19,902  565 565  -3,818 -326 -389  57 57 228,342 205,378 45,971 52,029 -6,149 -9,256 264,641 244,566 10 10



### **Consolidated Statements of Cash Flow**

CONFORM IFRS	Quarter ended 30/06/2016	Half Year ended 30/06/2016	Half Year ended 30/06/2015	Year ended 31/12/2015
(in k EUR)			audited	audited
Cash flow from operating activities				
Net income	23,135	45,971	52,029	99,071
Adjustments for :	23,133	.5,572	52,625	33,0.1
Operating activities	8,370	14,329	12,517	26,017
Deferred taxes	1,300	2,393	1,633	2,368
Capital grants	116	290	209	806
Depreciation and amortisation	6,290	11,766	11,443	22,809
Unrealized exchange results	863	448	-388	148
Financial result	-200	-568	-381	-114
Operating profit before working capital changes	31,506	60,300	64,545	125,089
A/R, Trade	-1,341	-2,882	-10,564	-10,890
A/R, affiliates	3,209	-5,112	-5,531	-415
Other current assets	-1,495	-2,786	-1,822	-421
Other non current assets	0	1	5	956
Inventories	-4,272	-2,530	-7,822	-10,551
A/P	3,234	6,457	1,549	1,342
A/P affiliates	9,111	9,606	2,712	4,632
Accrued expenses	394	3,910	2,068	6,505
Other current liabilities	164	-1,405	510	1,727
Other non current liabilities	-699	-1,390	-558	1,714
Interest paid	-59 -1,036	-128 -2,568	-188 -1,978	-383 -4,307
		-2,508		
Cash flow from operating activities		61 472	42 026	11/1000
Cash flow from operating activities	38,717	61,473	42,926	114,998
Cash flow from operating activities  Cash flow from investing activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received		-16,346 71 49	-18,163 139 -335	-40,281 361 -33
Cash flow from operating activities  Cash flow from investing activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted)	-8,662 54	-16,346 71	-18,163 139	-40,281 361
Cash flow from operating activities  Cash flow from investing activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments	-8,662 54	-16,346 71	-18,163 139	-40,281 361
Cash flow from operating activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Cash flows from financing activities  Payment to acquire own shares	-8,662 54 49 -8,559	-16,346 71 49	-18,163 139 -335 -18,358	-40,281 361 -33 -39,953
Cash flow from operating activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Payment to acquire own shares Proceeds/Repayment of long-and short-term debt Proceeds/Repayment of bank loans and overdrafts Proceeds from (repayment of) related party financing	-8,662 54 49 -8,559	-16,346 71 49 -16,226	-18,163 139 -335 -18,358	-40,281 361 -33 -39,953
Cash flow from operating activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Cash flows from financing activities  Payment to acquire own shares Proceeds/Repayment of long-and short-term debt Proceeds/Repayment of bank loans and overdrafts Proceeds from (repayment of) related party financing Impact of exchange results on financing items Dividend payment Capital Decrease	-8,662 54 49 -8,559	-16,346 71 49 -16,226	-18,163 139 -335 -18,358	-40,281 361 -33 -39,953 -3,010
Cash flow from operating activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Payment to acquire own shares Proceeds/Repayment of long-and short-term debt Proceeds/Repayment of bank loans and overdrafts Proceeds from (repayment of) related party financing Impact of exchange results on financing items Dividend payment	-8,662 54 49 -8,559	-16,346 71 49 -16,226	-18,163 139 -335 -18,358	-40,281 361 -33 -39,953
Cash flow from investing activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Cash flows from financing activities  Payment to acquire own shares Proceeds/Repayment of long-and short-term debt Proceeds/Repayment of bank loans and overdrafts Proceeds from (repayment of) related party financing Impact of exchange results on financing items Dividend payment Capital Decrease Non controlling interests  Cash used for financing activities	-8,662 54 49 -8,559 1 1 -781 -24,038	-16,346 71 49 -16,226 -46 333 -24,038	-18,163 139 -335 -18,358 4,912 -8,162	-40,281 361 -33 -39,953 -3,010 -5,738 -52,070
Cash flow from investing activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Cash flows from financing activities  Payment to acquire own shares Proceeds/Repayment of long-and short-term debt Proceeds/Repayment of bank loans and overdrafts Proceeds from (repayment of) related party financing Impact of exchange results on financing items Dividend payment Capital Decrease Non controlling interests  Cash used for financing activities	-8,662 54 49 -8,559 1 1 -781 -24,038	-16,346 71 49 -16,226  -46  333 -24,038	-18,163 139 -335 -18,358 4,912 -8,162	-40,281 361 -33 -39,953 -3,010 -5,738 -52,070
Cash flow from investing activities  Acquisition of subsidiary, net of cash acquired Financial fixed assets Purchase of PPE and intangible assets (netted) Interest received Investments/proceeds/ from current investments (incl. financial instruments)  Cash used for investing activities  Cash flows from financing activities  Payment to acquire own shares Proceeds/Repayment of long-and short-term debt Proceeds/Repayment of bank loans and overdrafts Proceeds from (repayment of) related party financing Impact of exchange results on financing items Dividend payment Capital Decrease Non controlling interests  Cash used for financing activities	-8,662 54 49 -8,559 1 1 -781 -24,038	-16,346 71 49 -16,226 -46 333 -24,038	-18,163 139 -335 -18,358 4,912 -8,162	-40,281 361 -33 -39,953 -3,010 -5,738 -52,070



# Sales per Geography

	Q2/16	Q2/15	Q1/16	HY 2016	HY 2015
APAC Asia Pacific	47%	47%	43%	45%	46%
EMEA Europe - Middle-East - Africa	39%	39%	43%	41%	39%
NALA North America - Latin America	14%	14%	14%	14%	15%
TOTAL	100%	100%	100%	100%	100%